United Therapeutics (UTHR) Tops Q4 EPS Views; Guides FY13 Revs
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $494.63 -0.53%
EPS Growth %: -10.1%
Financial Fact:
Selling, general and administrative: 100.1M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -10.1%
Financial Fact:
Selling, general and administrative: 100.1M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $1.65, $0.40 better than the analyst estimate of $1.25. Revenue for the quarter came in at $243.82 million versus the consensus estimate of $233.41 million.
United Therapeutics sees FY2013 revenue of $952.4 million to $1.05 billion, versus the consensus of $990.59 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
United Therapeutics sees FY2013 revenue of $952.4 million to $1.05 billion, versus the consensus of $990.59 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- B.Riley Assumes Anika Therapeutics (ANIK) at Buy
- Arrive AI and DXC Technology partner to bring delivery tech to factories
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
